MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318798 | Name: Temazepam

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NOTE: Temazepam has been discontinued | Temazepam is an intermediate-acting 3-hydroxy hypnotic of the benzodiazepine class of psychoactive drugs. It is the 3-hydroxy analogue of diazepam, and one of diazepam's primary active metabolites. Temazepam is approved for the short-term treatment of insomnia. In addition, temazepam has anxiolytic (antianxiety), anticonvulsant, and skeletal muscle relaxant properties.

Chemical Structure

Temazepam
Temazepam
CAS#846-50-4

Theoretical Analysis

MedKoo Cat#: 318798

Name: Temazepam

CAS#: 846-50-4

Chemical Formula: C16H13ClN2O2

Exact Mass: 300.0666

Molecular Weight: 300.74

Elemental Analysis: C, 63.90; H, 4.36; Cl, 11.79; N, 9.31; O, 10.64

Price and Availability

This product was removed for the commercial reasons.
Related CAS #
No Data
Synonym
ER115; ER-115; ER 115; Temazepam; Lenal; Levanxene
IUPAC/Chemical Name
7-chloro-3-hydroxy-1-methyl-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one
InChi Key
SEQDDYPDSLOBDC-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H13ClN2O2/c1-19-13-8-7-11(17)9-12(13)14(18-15(20)16(19)21)10-5-3-2-4-6-10/h2-9,15,20H,1H3
SMILES Code
O=C1N(C)C2=CC=C(Cl)C=C2C(C3=CC=CC=C3)=NC1O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 300.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kumar A, Chanana P, Choudhary S. Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs. Pharmacol Rep. 2016 Apr;68(2):231-42. doi: 10.1016/j.pharep.2015.09.002. Epub 2015 Sep 28. Review. PubMed PMID: 26922522. 2: Cardinali DP, Golombek DA, Rosenstein RE, Brusco LI, Vigo DE. Assessing the efficacy of melatonin to curtail benzodiazepine/Z drug abuse. Pharmacol Res. 2015 Oct 9. pii: S1043-6618(15)00184-X. doi: 10.1016/j.phrs.2015.08.016. [Epub ahead of print] Review. PubMed PMID: 26438969. 3: Mason M, Cates CJ, Smith I. Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2015 Jul 14;7:CD011090. doi: 10.1002/14651858.CD011090.pub2. Review. PubMed PMID: 26171909. 4: Amos T, Stein DJ, Ipser JC. Pharmacological interventions for preventing post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2014 Jul 8;7:CD006239. doi: 10.1002/14651858.CD006239.pub2. Review. PubMed PMID: 25001071. 5: Vinkers CH, Tijdink JK, Luykx JJ, Vis R. [Choosing the correct benzodiazepine: mechanism of action and pharmacokinetics]. Ned Tijdschr Geneeskd. 2012;155(35):A4900. Review. Dutch. PubMed PMID: 22929751. 6: Lee YA, Huynh P, Neher JO, Safranek S. Clinical Inquiry. What drugs are effective for periodic limb movement disorder? J Fam Pract. 2012 May;61(5):296-8. Review. PubMed PMID: 22577635. 7: Richards BL, Whittle SL, Buchbinder R. Muscle relaxants for pain management in rheumatoid arthritis. Cochrane Database Syst Rev. 2012 Jan 18;1:CD008922. doi: 10.1002/14651858.CD008922.pub2. Review. PubMed PMID: 22258993. 8: Medema RH, Macůrek L. Checkpoint control and cancer. Oncogene. 2012 May 24;31(21):2601-13. doi: 10.1038/onc.2011.451. Epub 2011 Oct 3. Review. PubMed PMID: 21963855. 9: Cañas F, Correll CU, Fagiolini A, Larmo I, Levy P, Papageorgiou G, Rossi A, Zink M, Montes JM. Practical guidance for prescribing ziprasidone in acute manic or mixed episodes of bipolar I disorder. Expert Opin Pharmacother. 2011 Oct;12(14):2245-63. doi: 10.1517/14656566.2011.605787. Epub 2011 Jul 30. Review. PubMed PMID: 21801083. 10: Starkey E, Sammons HM. Sedation for radiological imaging. Arch Dis Child Educ Pract Ed. 2011 Jun;96(3):101-6. doi: 10.1136/adc.2008.153072. Epub 2010 Jul 30. Review. PubMed PMID: 20675522. 11: Sériès F; Workshop Participants. Can improving sleep influence sleep-disordered breathing? Drugs. 2009;69 Suppl 2:77-91. doi: 10.2165/11532000-000000000-00000. Review. PubMed PMID: 20047352. 12: Wang SM, Chen BG, Wu MY, Liu RH, Lewis RJ, Ritter RM, Canfield DV. Mass Spectra and Cross-Contribution of Ion Intensity Between Drug Analytes and Their Isotopically Labelled Analogs - Benzodiazepines and Their Derivatives. Forensic Sci Rev. 2009 Jul;21(2):69-144. Review. PubMed PMID: 26242324. 13: Luks AM. Which medications are safe and effective for improving sleep at high altitude? High Alt Med Biol. 2008 Fall;9(3):195-8. doi: 10.1089/ham.2008.1025. Review. PubMed PMID: 18800955. 14: Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet. 2008;47(5):297-321. Review. PubMed PMID: 18399712. 15: Lagarde D. [Pharmacological approach to desychronization of the sleep-wakefulness cycle in the military and sport environment]. Ann Pharm Fr. 2007 Jul;65(4):258-64. Review. French. PubMed PMID: 17652994. 16: Rosenberg RP. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry. 2006 Jan-Mar;18(1):49-56. Review. PubMed PMID: 16517453. 17: Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 2005 Apr;106(1):97-132. Epub 2005 Jan 12. Review. PubMed PMID: 15781124. 18: Dündar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol. 2004 Jul;19(5):305-22. Review. PubMed PMID: 15252823. 19: Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297-328. Review. PubMed PMID: 15089115. 20: Morgan K, Dixon S, Mathers N, Thompson J, Tomeny M. Psychological treatment for insomnia in the regulation of long-term hypnotic drug use. Health Technol Assess. 2004 Feb;8(8):iii-iv, 1-68. Review. PubMed PMID: 14960254.